Figure 2.
OS at 12 months among YA patients receiving tisa-cel compared with those receiving brexu-cel. OS was 68% for YA patients receiving tisa-cel (95% CI, 56-85) and 84% for those receiving brexu-cel (95% CI, 81-100); HR, 1.8; 95% CI, 0.62-5.19; P = .35. OS was censored for the last follow-up.

OS at 12 months among YA patients receiving tisa-cel compared with those receiving brexu-cel. OS was 68% for YA patients receiving tisa-cel (95% CI, 56-85) and 84% for those receiving brexu-cel (95% CI, 81-100); HR, 1.8; 95% CI, 0.62-5.19; P = .35. OS was censored for the last follow-up.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal